Progress and opportunities for immune therapeutics in osteosarcoma

Christina K. Lettieri, Nicole Appel, Nicole Labban, Danielle M. Lussier, Joseph N. Blattman, Pooja Hingorani

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with relapsed or refractory disease have a particularly dismal outcome. Treatment options for these patients are limited primarily due to the paucity of effective therapeutics. Immune therapies such as tumor vaccines and traditional antigen-targeted monoclonal antibodies have had limited success in solid tumors. The recent discovery of novel immune checkpoint blockade strategies and their success in adult cancers has revitalized the use of immunotherapy strategies for the treatment of solid tumors. This paper summarizes existing data supporting the use of immune therapies in osteosarcoma and the progress of this class of drugs in osteosarcoma therapy.

Original languageEnglish (US)
Pages (from-to)1233-1244
Number of pages12
JournalImmunotherapy
Volume8
Issue number10
DOIs
StatePublished - Oct 2016

Keywords

  • clinical trials
  • immune checkpoint inhibitors
  • immune tolerance
  • immunotherapy
  • osteosarcoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Progress and opportunities for immune therapeutics in osteosarcoma'. Together they form a unique fingerprint.

  • Cite this

    Lettieri, C. K., Appel, N., Labban, N., Lussier, D. M., Blattman, J. N., & Hingorani, P. (2016). Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy, 8(10), 1233-1244. https://doi.org/10.2217/imt-2016-0048